Drugs / PF 06747143
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02954653 | Nov 2016 → Dec 2017 | acute myeloid leukemia | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF 06747143 | “PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.” NCT02954653 ↗ |
| Action | Inhibit | “an antagonist of CXCR4” NCT02954653 ↗ |
| Modality | Monoclonal antibody | “PF 06747143 is a humanized IgG1 monoclonal antibody (mAb)” NCT02954653 ↗ |
| Route | Intravenous | “Patients will receive intravenous (IV) PF-06747143” NCT02954653 ↗ |
| Target | CXCR4 | “an antagonist of CXCR4” NCT02954653 ↗ |